DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,088 filers reported holding DANAHER CORPORATION in Q2 2016. The put-call ratio across all filers is 0.21 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $50,688,472 | +5.8% | 204,307 | +2.5% | 3.38% | +9.6% |
| Q2 2023 | $47,889,664 | -2.5% | 199,322 | +2.4% | 3.08% | -7.8% |
| Q1 2023 | $49,093,408 | -1.9% | 194,603 | +3.2% | 3.34% | -8.0% |
| Q4 2022 | $50,066,595 | +2.6% | 188,482 | -0.1% | 3.63% | -8.3% |
| Q3 2022 | $48,790,000 | +2.3% | 188,743 | +0.5% | 3.96% | +1.7% |
| Q2 2022 | $47,682,000 | -12.5% | 187,895 | +1.1% | 3.89% | -4.1% |
| Q1 2022 | $54,498,000 | -10.3% | 185,790 | +0.6% | 4.06% | -4.1% |
| Q4 2021 | $60,752,000 | +14.2% | 184,650 | +5.6% | 4.23% | -3.9% |
| Q3 2021 | $53,216,000 | +4.3% | 174,798 | -8.1% | 4.41% | +11.8% |
| Q2 2021 | $51,037,000 | +18.4% | 190,180 | -0.7% | 3.94% | +9.5% |
| Q1 2021 | $43,100,000 | +0.0% | 191,486 | -1.3% | 3.60% | -6.1% |
| Q4 2020 | $43,081,000 | +6.5% | 193,938 | +3.2% | 3.83% | -9.2% |
| Q3 2020 | $40,460,000 | -21.8% | 187,898 | -35.8% | 4.22% | -21.9% |
| Q2 2020 | $51,762,000 | +23.9% | 292,721 | -3.0% | 5.41% | +7.8% |
| Q1 2020 | $41,761,000 | -13.2% | 301,718 | -3.8% | 5.02% | +11.3% |
| Q4 2019 | $48,117,000 | +6.1% | 313,506 | -0.1% | 4.51% | -2.1% |
| Q3 2019 | $45,337,000 | -0.2% | 313,904 | -1.2% | 4.61% | +0.5% |
| Q2 2019 | $45,413,000 | +6.8% | 317,752 | -1.4% | 4.58% | -0.6% |
| Q1 2019 | $42,532,000 | +26.9% | 322,164 | -0.8% | 4.61% | +13.1% |
| Q4 2018 | $33,504,000 | -6.8% | 324,907 | -1.8% | 4.08% | +9.7% |
| Q3 2018 | $35,944,000 | +10.2% | 330,794 | +0.0% | 3.72% | +2.0% |
| Q2 2018 | $32,628,000 | +10.5% | 330,642 | +9.7% | 3.64% | +9.5% |
| Q1 2018 | $29,521,000 | +8.5% | 301,507 | +2.9% | 3.33% | +11.4% |
| Q4 2017 | $27,207,000 | +9.6% | 293,118 | +1.3% | 2.99% | +3.9% |
| Q3 2017 | $24,818,000 | +1.9% | 289,323 | +0.2% | 2.88% | -8.2% |
| Q2 2017 | $24,361,000 | +2.1% | 288,672 | +3.4% | 3.13% | +1.0% |
| Q1 2017 | $23,871,000 | +18.6% | 279,091 | +7.9% | 3.10% | +13.6% |
| Q4 2016 | $20,131,000 | +3.9% | 258,623 | +4.7% | 2.73% | -4.5% |
| Q3 2016 | $19,367,000 | -21.1% | 247,056 | +1.7% | 2.86% | -24.5% |
| Q2 2016 | $24,532,000 | – | 242,888 | – | 3.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |